SeaStar Medical reported a 247% increase in net revenue for Q3 2026, driven by growing adoption of its QUELIMMUNE therapy for pediatric acute kidney injury (AKI). The company has enrolled nearly 75% of patients in its NEUTRALIZE-AKI pivotal trial for adult AKI treatment and submitted the first FDA premarket approval module. QUELIMMUNE showed statistically significant survival benefits in pediatric patients, and SeaStar received FDA Breakthrough Device Designation for its SCD therapy. The company posted a net loss of $4.5 million in Q3 but is advancing regulatory and clinical milestones that could expand treatment options for critically ill AKI patients.
SeaStar Medical's Q3 2026 financial results provide context for readers following health sector developments. For readers following the health sector, here is Pluang's market snapshot as of Nov 12, 2026 04:11 WIB: Of 150 priced health-sector US stocks tradable on Pluang, 87 rose and 61 fell today. Notable movers include TWST at USD 124.10 with a 1-day change of -6.08% and a typical hold time of 27 days, RVMD at USD 181.41 down 6.03% with a 13-day hold, and COGT at USD 29.83 down 5.72% with a 7-day hold and 100% buy order activity.
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
Tennessee American Water has applied an additional $13.07 credit to customer accounts, bringing total PFAS settlement refunds to over $84 per customer. This credit follows approval from the Tennessee Public Utility Commission, allowing the company to...
